A major test suggests that the recently launched tricolor in India helps people to lose overweight and reduce your waist faster than semaglutide.

A new study has found that a weight loss injection introduced in India in this march is more effective than tirzepetides, semaglutides, which is a popular obesity already available in the country.

In a clinical trial lasting 72 weeks, people who took Tirzepatide lost an average of about 23 kg, while Semaglutide people lost about 15 kg.

Both drugs were given through injections once a week, and participants also followed a controlled diet and exercised regularly.

Research published in the New England Journal of Medicine showed that Tirzepetides also helped people to reduce more abdominal fat, with a decline of 7.2 inches, with a decline of 7.2 inches, compared to 5.1 inches with semaglutide.

Tirzepatide is sold under the brand name Mounjaro developed by US-based company Elli Lily. It is a dual-action drug (dual GIP and GLP-1 receptor agonist), which means that it targets two hormones that control hunger and blood sugar. It helps people feel as soon as possible and eat less.

Semaglutide created by Danish drug manufacturer Novo Nordisk works in a similar way, but works on just a hormone (mono GLP -1 receptor agonist). There is a lower-khurak pill version of Rybelsus in India since 2022, but more powerful injections (ozmpic and vegovi) have not yet been launched here.

Novo Nordisk has confirmed the plan to bring Vagovi to India later this year.

In the study, 65% of people who took tirzepetide, lost at least 15% of their body weight, compared to 40% of semaglutide.

“This is a major step in the treatment of obesity, a serious long -term health status,” said Lily India President and General Manager Vinslo Tucker.

The test consisted of 751 participants of the US and Puerto Rico, all of which were either coarse (over 30 BMI) or overweight (BMI 25-30) such as other health issues such as high blood pressure, sleep apnea, or heart disease, but no one had diabetes.

All were advised to diet and exercise, in addition to weekly injections.

Side effects and safety

Like many weight -loss drugs, both tirzepetides and semglutides cause mildly moderate side effects, mainly stomach related issues such as nausea, vomiting and inflammation.

A small number of people stopped taking drugs due to side effects, about 6% on tirzepetides and 8% on semaglutide.

Researchers stated that while the test was not designed to directly compare the safety of both drugs, the conclusions corresponds to earlier studies.

There are both tirzepatide and semaglutide tips-a doctor should be taken under the supervision of a doctor. They are not for short -term or cosmetic use, and regular monitoring is required to manage side effects.